The EpiGASTRIC/EDGAR Project: New Strategies for the Early Detection and Prevention of Gastric Cancer
Launched by EDUARDO ALBENIZ · Sep 19, 2022
Trial Information
Current as of July 09, 2025
Recruiting
Keywords
ClinConnect Summary
The EpiGASTRIC/EDGAR Project is a clinical trial aimed at finding new ways to detect and prevent gastric cancer, which is a type of stomach cancer. The study will involve at least 600 patients who have been diagnosed with gastric cancer, about 50 patients with early signs of cancer, and 600 healthy individuals. Over the course of more than 18 months, researchers will collect information about participants' health habits, clinical data, and biological samples to help develop better diagnostic tools to identify people who are at high risk for gastric cancer. The goal is to catch the disease early and reduce the number of deaths from it.
To participate in this study, individuals must be adults over 18 years old. There are specific groups of people being recruited: those who have symptoms leading to a gastroscopy (a procedure where a doctor looks inside the stomach), those with early signs of gastric cancer who need further treatment, and healthy individuals with no gastric issues. Participants can expect to answer questions about their lifestyle, undergo some medical evaluations, and provide samples for research. It's important to know that individuals who have had previous gastric surgeries or specific medical conditions might not be eligible to join. This study aims to make a significant impact on how gastric cancer is detected and treated in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adults over 18 years-old.
- • EDGAR 1 cohort: symptomatic patients undergoing a diagnostic gastroscopy for a prevalence study of PGLs.
- • EDGAR 2 cohort: PGLs and early GC with indication for endoscopic resection.
- • EPIGASTRIC cohort: patients diagnosed with GC.
- • CONTROL cohort: patients without gastric pathology or a familial history of GC, obtained from the EDGAR 1.
- Exclusion Criteria:
- • Refusal of the patient to participate in the study.
- • Medical, psychological or legal inability of the patient to enter the study.
- • EDGAR1: Previous diagnosis of PGLs, previous gastric surgery, contraindication for gastroscopy or taking biopsies.
- • EDGAR 2: Contraindication for resection/biopsy.
- • EPIGASTRIC: gastric neoplasm other than adenocarcinoma.
About Eduardo Albeniz
Eduardo Albeniz is a dedicated clinical trial sponsor committed to advancing medical research and innovation through rigorous study design and execution. With a focus on developing effective therapies across various therapeutic areas, Mr. Albeniz leverages his extensive expertise in clinical operations and regulatory compliance to ensure that trials meet the highest standards of safety and efficacy. His collaborative approach fosters strong partnerships with healthcare professionals and institutions, facilitating the timely and ethical advancement of novel treatments. Through a commitment to transparency and scientific integrity, Eduardo Albeniz plays a pivotal role in enhancing patient care and outcomes in the evolving landscape of clinical research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Gerona, , Spain
Zaragoza, , Spain
Terrassa, Barcelona, Spain
Zaragoza, , Spain
Oviedo, Asturias, Spain
Majadahonda, Madrid, Spain
Barcelona, , Spain
Granollers, Barcelona, Spain
Burgos, , Spain
Pamplona, Navarra, Spain
Aranda De Duero, Burgos, Spain
Palma De Mallorca, Baleares, Spain
Porto Cristo, Baleares, Spain
Mérida, Extremadura, Spain
Ourense, Galicia, Spain
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials